Blinded sample size re-estimation for recurrent event data with time trends

Statistics in Medicine

Volumn 32, Issue 30, 2013, Pages 5448-5457

  Schneider, S ^a   Schmidli, H ^b   Friede, T ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adaptive design; Blinded sample size re estimation; Clinical trials; Event counts; Sample size

Indexed keywords

ALGORITHM; ANALYTIC METHOD; ANALYTICAL ERROR; ARTICLE; BINOMIAL DISTRIBUTION; BLINDED SAMPLE SIZE RE ESTIMATION; FOLLOW UP; HUMAN; HYPOTHESIS; MATHEMATICAL COMPUTING; MULTIPLE SCLEROSIS; PROBABILITY; RECURRENT DISEASE; SAMPLE SIZE; SIMULATION;

ADAPTIVE DESIGN; BLINDED SAMPLE SIZE RE-ESTIMATION; CLINICAL TRIALS; EVENT COUNTS; SAMPLE SIZE;

COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; HUMANS; LIKELIHOOD FUNCTIONS; MODELS, STATISTICAL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PILOT PROJECTS; RECURRENCE; SAMPLE SIZE;

EID: 84897073743     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5977     Document Type: Article

References (34)

1. Wittes J, Brittain E. The role of internal pilot studies in increasing the efficacy of clinical trials. Statistics in Medicine 1990; 9: 65-72.
2. ICH. ICH harmonised tripartite guideline E9: statistical principles for clinical trials. Statistics in Medicine 1999; 18: 1905-1942.
3. Committee for Medicinal Products for Human Use (CHMP). Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. CHMP/EWP/2459/02, 2007. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003616.pdf [Accessed 4 September 2013].
4. Food and Drug Administration (FDA). Guidancefor industry - Adaptive design clinical trials for drugs and biologics. Draft guidance, 2010. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm201790.pdf [Accessed 4 September 2013].
5. Proschan M. Two-stage sample size reestimation based on a nuisance parameter: a review. Journal of Biopharmaceutical Statistics 2005; 15: 559-574.
6. Proschan MA. Sample size re-estimation in clinical trials. Biometrical Journal 2009; 51: 348-357.
7. Friede T, Kieser M. Sample size recalculation ininternal pilot study designs: a review. Biometrical Journal 2006; 48: 537-555.
8. Sormani MP, Bruzzi P, Miller DH, Gasperini C, Barkhof F, Filippi M. Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials. Journal of Neurological Sciences 1999; 163: 74-80.
9. van den Elskamp I, Knol D, Uitdehaag B, Barkhof F. The distribution of newenhancing lesion counts in multiple sclerosis: further explorations. Multiple Sclerosis 2009; 15: 42-49.
10. Wang YC, Meyerson L, Tang YQ, Qian N. Statistical methods for the analysis of relapse data in MS clinical trials. Journal of Neurological Sciences 2009; 285: 206-211.
11. Hilbe JM. Negative Binomial Regression. Cambridge University Press: Cambridge, 2007.
12. Nicholas R, Straube S, Schmidli H, Schneider S, Friede T. (2011) Trends in annualized relapse rates in relapsing remitting multiple sclerosis and consequences for clinical trial design. Multiple Sclerosis Journal 2011; 17: 1211-1217.
13. Friede T, Schmidli H. Blinded sample size reestimation with count data: methods and applications in multiple sclerosis. Statistics in Medicine 2010; 29: 1145-1156.
14. Friede T, Schmidli H. Blinded sample size reestimation with negative binomial counts in superiority and non-inferiority trials. Methods of Information in Medicine 2010; 49: 618-624.
15. Schneider S, Schmidli H, Friede T. Robustness of methods for blinded sample size re-estimation with overdispersed count data. Statistics in Medicine 2013; 32: 3623-3635.
16. Nicholas R, Straube S, Schmidli H, Pfeiffer S, Friede T. Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis. Multiple Sclerosis Journal 2012; 18(9):1290-1296.
17. Cook RJ, Bergeron PJ, Boher JM, Lie Y. Two-stage design of clinical trials involving recurrent events. Statistics in Medicine 2009; 28: 2617-2638.
18. Lawless J. Regression methods for Poisson process data. Journal of the American Statistical Association Theory and Methods 1987; 82: 808-815.
19. Matsui S. Sample size calculations for comparative clinical trials with over-dispersed Poisson process data. Statistics in Medicine 2005; 24: 1339-1356.
20. Cook J, Lawless J. The Statistical Analysis of Recurrent Events. Springer: Berlin, 2007.
21. Dean CB, Balshaw R. Efficiency lost by analyzing counts rather than even times in poisson and overdispersed poisson regression models. Journal of the American Statistical Association 1997; 92(440):1387-1398.
22. R Development Core Team, 2009. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, ISBN:3-900051-07-0. http://www.R-project.org [Accessed 4 September 2013].
23. Keene ON, Jones MRK, Lane PW, Anderson J. Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study. Pharmaceutical Statistics 2007; 6: 89-97.
24. Schneider S, Schmidli H, Friede T. Blinded and unblinded internal pilot study designs for clinical trials with count data. Biometrical Journal 2013; 55: 617-633.
25. Nicholas R, Friede T. Considerations in the design of clinical trials for relapsing multiple sclerosis. Clinical Investigation 2012; 2: 1073-1083.
26. Steinvorth S, Röver C, Schneider S, Nicholas R, Straube S, Friede T. Temporal trends in baseline characteristics and eligibility criteria in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: A systematic review. Multiple Sclerosis Journal 2013. DOI: 10.1177/1352458513481009.
27. Akacha M, Benda N. The impact of dropouts on the analysis of dose-finding studies with recurrent event data. Statistics in Medicine 2010; 29: 1635-1646.
28. Jenkins CR, Celli B, Anderson JA, Ferguson GT, Jones PW, Yates JC, Calverley PM. Seasonality and determinants of moderate and severe COPD exacerbations in TORCH study. The European respiratory journal 2012; 39: 1-38.
29. Gurka MJ, Coffey CS, Gurka KK. Internal pilots for observational studies. Biometrical Journal 2010; 52: 590-603.
30. Chen Q, Zeng D, Ibrahim JG, Akacha M, Schmidli H. Estimating time-varying effects for overdispersed recurrent events data with treatment switching. Biometrika 2013; 100: 339-354.
31. Aalen OO. A linear regression model for the analysis of life-times. Statistics in Medicine 1989; 8: 907-925.
32. Cai J, Zeng D. Additive mixed effect model for clustered failure time data. Biometrics 2001; 67: 1340-1351.
33. Martinussen T, Scheike TH, Zucker D. The Aalen additive gamma fraily hazarads model. Biometrika 2011; 98: 831-843.
34. Hua L, Zhang Y. Spline-Based Semiparametric Sieve Maximum Likelihood Method for Over-dispersed Panel Count Data. The technical report can be downloaded from http://www.public-health.uiowa.edu/BIOSTAT/research/documents/TechnicalReport-HuaZhang.pdf [Accessed 4 September 2013].